To investigate whether treatment status affected sensitivity to MEK/Bcl‐2 inhibition, we performed the same analysis on a cohort of CLL patients that were treated with the PI3K inhibitor idelalisib as first line or following chemoimmunotherapy (‘JB’ patients listed in Table 2) [8]. Here, MAP2K7 is linked to B-cell chronic lymphocytic leukemia.